This week's budget assumes all Australians will have the chance to be fully vaccinated by the end of the year. It's ambitious but possible.
Vanquishing the enemy? People stand in a quick moving line up at a mass vaccination centre during the COVID-19 pandemic in Mississauga, Ont., on May 10, 2021.
THE CANADIAN PRESS/Nathan Denette
Public officials are telling us simultaneously to move swiftly on vaccination and also to make thoughtful, reasoned choices about which vaccine we get. These messages are confusing and frustrating.
People line up at a mass vaccination centre during the COVID-19 pandemic in Mississauga, Ont.
THE CANADIAN PRESS/Nathan Denette
Canadian public health organizations have run into a serious communication problem about the AstraZeneca vaccine. Crisis management and communication theories explain what's gone wrong.
The AstraZeneca COVID vaccine is now available to Australians over 50. Here's what you need to know before you roll up your sleeve.
Covid-19 vaccination strategies have been affected by supply woes.
The COVID-19 vaccination programme requires stringent data collection and transparency.
At the end of 2020, India applied to the WTO for a temporary suspension of intellectual property rights related to Covid-19.
Licensing agreements between pharmaceutical companies and the Medicines Patent Pool, in cooperation with the WHO, could accelerate access to doses for the poorest countries.
Australia was promised a world-class vaccine program. But instead of a rollout, we got an eekout.
The amount of risk from overseas arrivals depends not just on Australia's vaccination rates, but also on the particular circumstances of the country from which people are travelling.
Hospital staff in Lagos, Nigeria, administer the AstraZeneca vaccine.
AP Photo/Sunday Alamba
India and South Africa are pressing the World Trade Organization to waive patent rights to help ramp up vaccine production. There's a better solution.
Generally speaking, fault can only be proven when the doctor has acted outside of the professional standard of care.
COVAX, the global vaccine distribution initiative, is well behind its goal of delivering 2 billion doses this year due to under-investment, vaccine nationalism and export restrictions.
The challenge now is to address the understandable concerns and prevent them from contaminating the broader public dialogue on COVID-19 vaccination.
The AstraZeneca vaccine was 70 per cent effective against symptomatic COVID-19 infection in a large multinational study, and recently reported 76 per cent overall efficacy against symptomatic COVID-19 in another large study done primarily in the United States.
THE CANADIAN PRESS/John Woods
With changing recommendations about AstraZeneca's COVID-19 vaccine making headlines, many people have questions about its use.
This week's unwelcome medical advice about the AstraZeneca vaccine is the latest setback to the rollout and the Morrison government.
This shift in focus away from AstraZeneca to the Pfizer vaccine has serious impacts on the timing of the rollout and public confidence in the AstraZeneca vaccine.
A healthcare worker administers an Oxford/AstraZeneca COVID-19 vaccine to her colleague at Mutuini Hospital in Nairobi. Kenya on March 3, 2021.
Photo by Dennis Sigwe/SOPA Images/LightRocket via Getty Images
Kenya grapples with two major challenges in the vaccination rollout: access to sufficient doses in light of the global shortage; and vaccine hesitancy.
The vaccine rollout was thrown into fresh uncertainty on Thursday night after the government received medical advice against using the AstraZeneca vaccine for people under 50 because of the very small risk of blood clots.
Luong Thai Linh/AAP
Stephen Duckett on what’s wrong with the rollout.
Michelle Grattan discusses the vaccine rollout with Stephen Duckett.
Charlie J Ercilla / Alamy Stock Photo
Good news for children and young people, bad news for Johnson & Johnson.
These mistakes have been mainly caused by our leaders giving priority to a good political story over good policy.